UnicoCell Biomed Co., Ltd.

TW:6794 Taiwan Biotechnology
Market Cap
$153.87 Million
NT$5.09 Billion TWD
Market Cap Rank
#21050 Global
#1126 in Taiwan
Share Price
NT$80.00
Change (1 day)
+1.78%
52-Week Range
NT$78.50 - NT$92.00
All Time High
NT$92.00
About

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; CDMO; UnicoVial, a cryogenic vial for the storage of cel… Read more

UnicoCell Biomed Co., Ltd. - Asset Resilience Ratio

Latest as of June 2025: 66.74%

UnicoCell Biomed Co., Ltd. (6794) has an Asset Resilience Ratio of 66.74% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
NT$555.38 Million
Cash + Short-term Investments
Total Assets
NT$832.20 Million
All company assets
Resilience Assessment
Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how UnicoCell Biomed Co., Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down UnicoCell Biomed Co., Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents NT$0.00 0%
Short-term Investments NT$555.38 Million 66.74%
Total Liquid Assets NT$555.38 Million 66.74%

Asset Resilience Insights

  • Very High Liquidity: UnicoCell Biomed Co., Ltd. maintains exceptional liquid asset reserves at 66.74% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

UnicoCell Biomed Co., Ltd. Industry Peers by Asset Resilience Ratio

Compare UnicoCell Biomed Co., Ltd.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for UnicoCell Biomed Co., Ltd. (2019–2024)

The table below shows the annual Asset Resilience Ratio data for UnicoCell Biomed Co., Ltd..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 69.93% NT$543.95 Million NT$777.89 Million +3.25pp
2023-12-31 66.68% NT$457.38 Million NT$685.93 Million +28.00pp
2022-12-31 38.68% NT$160.25 Million NT$414.31 Million +35.26pp
2021-12-31 3.42% NT$10.17 Million NT$297.71 Million +0.84pp
2020-12-31 2.58% NT$10.09 Million NT$391.22 Million -0.23pp
2019-12-31 2.81% NT$10.00 Million NT$356.17 Million --
pp = percentage points